Clotting Activation and Hyperfibrinolysis in Cirrhosis: Implication for Bleeding and Thrombosis

 

 Buy Article Permissions and Reprints

Abstract

Hyperfibrinolysis may be detected in patients with cirrhosis, particularly in case of severe liver failure. Hyperfibrinolysis is usually associated with prolonged global tests of clotting activation, which are then dependent on impaired synthesis of clotting factors by liver cells. The term “coagulopathy” has therefore been coined to indicate the existence of hyperfibrinolysis and blood hypocoagulation in cirrhosis, and, for a long time, these changes have been believed to facilitate bleeding. However, apart from gastrointestinal bleeding, which is related prevalently to hemodynamic factors in the portal circulation, spontaneous bleeding is less frequent than would be expected by the abnormality of laboratory tests. This apparent paradox may be explained by studies questioning the term “coagulopathy,” instead documenting a hypercoagulation state in portal as well as in peripheral circulation of cirrhotic patients. The support of these findings by more recent data allows a redefinition of the overall clotting picture, in particular hyperfibrinolysis, in cirrhosis. Thus, this review analyzes prevalence and clinical impact of hyperfibrinolysis in cirrhosis, focusing in particular on whether it is primary or secondary to clotting activation. Furthermore, we focused such changes in the context of more recent data showing an association between cirrhosis and thrombosis.

• References

• 1 Roberts HR, Cederbaum AI. The liver and blood coagulation: physiology and pathology. Gastroenterology 1972; 63 (2) 297-320
  PubMedGoogle Scholar
• 2 Brozovic M. Acquired disorders of coagulation. In: Bloom AL, Thomas DP, eds. Hemostasis and Thrombosis. Edinburgh, UK: Churchill Livingstone; 1987: 519-534
  Google Scholar
• 3 Joist JH. Hemostatic abnormalities in liver disease. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 2nd ed. Philadelphia, Lippincott: 1987: 861-872
  Google Scholar
• 4 Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007; 24 (4) 250-258
  CrossrefPubMedGoogle Scholar
• 5 Brodsky I, Dennis LH. Evaluation of fibrinolysis in hepatic cirrhosis. Relation of serial thrombin time and euglobulin lysis time. Am J Clin Pathol 1966; 45 (1) 61-69
  PubMedGoogle Scholar
• 6 Aytac S, Turkay C, Bavbek N, Kosar A. Hemostasis and global fibrinolytic capacity in chronic liver disease. Blood Coagul Fibrinolysis 2007; 18 (7) 623-626
  CrossrefPubMedGoogle Scholar
• 7 Violi F, Leo R, Davì G, Praticò D, Iuliano L, Balsano F. Thrombocytopenia and thrombocytopathia in liver cirrhosis. Platelets 1992; 3: 233-239
  PubMedGoogle Scholar
• 8 Tripodi A, Primignani M, Chantarangkul V , et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137 (6) 2105-2111
  CrossrefPubMedGoogle Scholar
• 9 Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 12 (48) 7725-7736
  PubMedGoogle Scholar
• 10 Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94 (10) 2801-2803
  PubMedGoogle Scholar
• 11 Goodpasture EW. Fibrinolysis in chronic hepatic insufficiency. Bull Johns Hopkins Hosp 1914; 25: 330-332
  PubMedGoogle Scholar
• 12 Kwaan HC, McFadzean AJ, Cook J. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet 1956; 270 (6908) 132-136
  PubMedGoogle Scholar
• 13 Leebek FW, Kluft C, Knot EA et al. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterol 1991; 101: 1382-1390
  PubMedGoogle Scholar
• 14 Violl F, Basili S, Ferro D, Quintarelli C, Alessandril C, Cordova C. CALC Group. Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. Thromb Haemost 1996; 76 (2) 177-183
  PubMedGoogle Scholar
• 15 Violi F, Ferro D, Basili S , et al; CALC Group. Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. Hepatology 1995; 22 (1) 96-100
  PubMedGoogle Scholar
• 16 Aoki N, Yamanaka T. The alpha2-plasmin inhibitor levels in liver diseases. Clin Chim Acta 1978; 84 (1-2) 99-105
  CrossrefPubMedGoogle Scholar
• 17 Knot EA, Drijfhout HR, ten Cate JW , et al. Alpha 2-plasmin inhibitor metabolism in patients with liver cirrhosis. J Lab Clin Med 1985; 105 (3) 353-358
  PubMedGoogle Scholar
• 18 Gram J, Jespersen J, Ingeberg S, Bentsen KD, Bach E. Plasma histidine-rich glycoprotein and plasminogen in patients with liver disease. Thromb Res 1985; 39 (4) 411-417
  CrossrefPubMedGoogle Scholar
• 19 Biland L, Duckert F, Prisender S, Nyman D. Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb Haemost 1978; 39 (3) 646-656
  PubMedGoogle Scholar
• 20 Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984; 37 (7) 772-777
  CrossrefPubMedGoogle Scholar
• 21 Rijken DC, Emeis JJ. Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. Biochem J 1986; 238 (3) 643-646
  PubMedGoogle Scholar
• 22 Hersch SL, Kunelis T, Francis Jr RB. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987; 69 (5) 1315-1319
  PubMedGoogle Scholar
• 23 Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85 (4) 667-670
  PubMedGoogle Scholar
• 24 Colucci M, Binetti BM, Branca MG , et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38 (1) 230-237
  PubMedGoogle Scholar
• 25 Francis Jr RB, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984; 14 (6) 460-465
  PubMedGoogle Scholar
• 26 Bertaglia E, Belmonte P, Vertolli U, Azzurro M, Martines D. Bleeding in cirrhotic patients: a precipitating factor due to intravascular coagulation or to hepatic failure?. Haemostasis 1983; 13 (5) 328-334
  PubMedGoogle Scholar
• 27 Violi F, Ferro D, Basili S , et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992; 15 (4) 672-676
  CrossrefPubMedGoogle Scholar
• 28 Tripodi A, Mannucci PMM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (2) 147-156
  CrossrefPubMedGoogle Scholar
• 29 Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 6 (1) 79-86
  CrossrefPubMedGoogle Scholar
• 30 Violi F, Ferro D, Basili S , et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. Hepatology 1993; 17 (1) 78-83
  CrossrefPubMedGoogle Scholar
• 31 Caldwell SH, Hoffman M, Lisman T , et al; Coagulation in Liver Disease Group. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44 (4) 1039-1046
  CrossrefPubMedGoogle Scholar
• 32 D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 1988; 81 (5) 1445-1454
  CrossrefPubMedGoogle Scholar
• 33 Tripodi A, Primignani M, Lemma L , et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010; 52 (1) 249-255
  CrossrefPubMedGoogle Scholar
• 34 Lumsden AB, Henderson JM. Kutner Mh Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatol 1988; 8: 232-236
  CrossrefPubMedGoogle Scholar
• 35 Violi F, Ferro D, Basili S , et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995; 109 (2) 531-539
  CrossrefPubMedGoogle Scholar
• 36 Semeraro N, Biondi A, Lorenzet R, Locati D, Mantovani A, Donati MB. Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites. Immunology 1983; 50 (4) 529-535
  PubMedGoogle Scholar
• 37 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79 (1) 124-130
  CrossrefPubMedGoogle Scholar
• 38 Ferro D, Quintarelli C, Lattuada A , et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23 (6) 1377-1383
  CrossrefPubMedGoogle Scholar
• 39 O'Donnell J, Mumford AD, Manning RA, Laffan MA. Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol 2001; 115 (3) 687-691
  CrossrefPubMedGoogle Scholar
• 40 Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91 (2) 267-275
  PubMedGoogle Scholar
• 41 Saliola M, Lorenzet R, Ferro D , et al. Enhanced expression of monocyte tissue factor in patients with liver cirrhosis. Gut 1998; 43 (3) 428-432
  CrossrefPubMedGoogle Scholar
• 42 Ferro D, Angelico F, Caldwell SH, Violi F. Bleeding and thrombosis in cirrhotic patients: what really matters?. Dig Liver Dis 2012; 44 (4) 275-279
  CrossrefPubMedGoogle Scholar
• 43 Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?. J Hepatol 2011; 55 (6) 1415-1427
  CrossrefPubMedGoogle Scholar
• 44 Basili S, Raparelli V, Riggio O , et al; CALC Group. NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. Liver Int 2011; 31 (10) 1533-1540
  CrossrefPubMedGoogle Scholar
• 45 Pignatelli P, Carnevale R, Di Santo S , et al. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 2011; 31 (2) 423-434
  CrossrefPubMedGoogle Scholar
• 46 Huang H-H, Lin H-H, Shih YL , et al. Spontaneous intracranial hemorrhage in cirrhotic patients. Clin Neurol Neurosurg 2008; 110 (3) 253-258
  CrossrefPubMedGoogle Scholar
• 47 Northup PG, McMahon MM, Ruhl AP , et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101 (7) 1524-1528 , quiz 1680
  CrossrefPubMedGoogle Scholar
• 48 García-Fuster MJ, Abdilla N, Fabiá MJ, Fernández C, Oliver V, Forner MJ. [Venous thromboembolism and liver cirrhosis]. Rev Esp Enferm Dig 2008; 100 (5) 259-262
  PubMedGoogle Scholar
• 49 Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008; 53 (11) 3012-3017
  CrossrefPubMedGoogle Scholar
• 50 Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104 (1) 96-101
  CrossrefPubMedGoogle Scholar
• 51 Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol 2010; 8 (9) 800-805
  CrossrefPubMedGoogle Scholar
• 52 Janssen HL, Wijnhoud A, Haagsma EB , et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001; 49 (5) 720-724
  CrossrefPubMedGoogle Scholar
• 53 Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006; 12 (13) 2115-2119
  CrossrefPubMedGoogle Scholar
• 54 Okuda K, Ohnishi K, Kimura K , et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985; 89 (2) 279-286
  PubMedGoogle Scholar
• 55 Belli L, Romani F, Sansalone CV, Aseni P, Rondinara G. Portal thrombosis in cirrhotics. A retrospective analysis. Ann Surg 1986; 203 (3) 286-291
  CrossrefPubMedGoogle Scholar
• 56 Orloff MJ, Orloff MS, Orloff SL, Girard B. Portal vein thrombosis in cirrhosis with variceal hemorrhage. J Gastrointest Surg 1997; 1 (2) 123-130 , discussion 130–131
  CrossrefPubMedGoogle Scholar
• 57 Sarfeh IJ. Portal vein thrombosis associated with cirrhosis: clinical importance. Arch Surg 1979; 114 (8) 902-905
  CrossrefPubMedGoogle Scholar
• 58 Fimognari FL, De Santis A, Piccheri C , et al. Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. J Lab Clin Med 2005; 146 (4) 238-243
  CrossrefPubMedGoogle Scholar
• 59 Gaiani S, Bolondi L, Li BS , et al. Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis. Clinical and endoscopic correlation in 228 patients. Gastroenterol 1991; 100: 160-167
  PubMedGoogle Scholar
• 60 Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis 2010; 42 (3) 163-170
  CrossrefPubMedGoogle Scholar
• 61 Nonami T, Yokoyama I, Iwatsuki S, Starzl TE. The incidence of portal vein thrombosis at liver transplantation. Hepatology 1992; 16 (5) 1195-1198
  CrossrefPubMedGoogle Scholar
• 62 Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 31 (3) 366-374
  CrossrefPubMedGoogle Scholar
• 63 Amitrano L, Guardascione MA, Menchise A , et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44 (6) 448-451
  PubMedGoogle Scholar
• 64 Francoz C, Belghiti J, Vilgrain V , et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54 (5) 691-697
  CrossrefPubMedGoogle Scholar
• 65 Martinelli I, Primignani M, Aghemo A , et al. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol 2009; 50 (5) 916-922
  CrossrefPubMedGoogle Scholar
• 66 Violi F, Ferro D, Basili S , et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost 1997; 77 (1) 44-47
  Article in Thieme ConnectPubMedGoogle Scholar
• 67 Violi F, Ferro D, Quintarelli C , et al. Dilute aPTT prolongation by antiphospholipid antibodies in patients with liver cirrhosis. Thromb Haemost 1990; 63 (2) 183-186
  PubMedGoogle Scholar
• 68 Quintarelli C, Ferro D, Valesini G, Basili S, Tassone G, Violi F. Prevalence of lupus anticoagulant in patients with cirrhosis: relationship with beta-2-glycoprotein I plasma levels. J Hepatol 1994; 21 (6) 1086-1091
  CrossrefPubMedGoogle Scholar
• 69 Violi F, Ferro D, Basili S , et al. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. BMJ 1994; 309 (6949) 239-240
  CrossrefPubMedGoogle Scholar
• 70 Mangia A, Margaglione M, Cascavilla I , et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol 1999; 94 (10) 2983-2987
  CrossrefPubMedGoogle Scholar
• 71 Oksüzoglu G, Bayraktar Y, Arslan S , et al. Portal vein thrombosis in cirrhotics: related with anticardiolipin antibodies?. Hepatogastroenterology 2003; 50 (53) 1527-1530
  PubMedGoogle Scholar
• 72 Romero Gómez M, Suárez García E, López Lacomba D, Marchante I, Grande L, Castro Fernandez M. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2000; 31 (3) 237-240
  CrossrefPubMedGoogle Scholar
• 73 Zocco MA, Di Stasio E, De Cristofaro R , et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51 (4) 682-689
  CrossrefPubMedGoogle Scholar
• 74 Lin HC, Yang YY, Tsai TH , et al. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. J Hepatol 2011; 54 (6) 1145-1153
  CrossrefPubMedGoogle Scholar
• 75 Amitrano L, Guardascione MA, Brancaccio V , et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40 (5) 736-741
  CrossrefPubMedGoogle Scholar
• 76 Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21 (5) 1238-1247
  CrossrefPubMedGoogle Scholar
• 77 Lendoire J, Raffin G, Cejas N , et al. Liver transplantation in adult patients with portal vein thrombosis: risk factors, management and outcome. HPB (Oxford) 2007; 9 (5) 352-356
  CrossrefPubMedGoogle Scholar
• 78 Selvaggi G, Weppler D, Nishida S , et al. Ten-year experience in porto-caval hemitransposition for liver transplantation in the presence of portal vein thrombosis. Am J Transplant 2007; 7 (2) 454-460
  CrossrefPubMedGoogle Scholar
• 79 Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int 2012; 32 (10) 1465-1476
  CrossrefPubMedGoogle Scholar
• 80 Villa E, Cammà C, Marietta M , et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterol 2012; ; In press
  PubMedGoogle Scholar
• 81 Connolly SJ, Ezekowitz MD, Yusuf S , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
  CrossrefPubMedGoogle Scholar
• 82 Mega JL, Braunwald E, Wiviott SD , et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (1) 9-19
  CrossrefPubMedGoogle Scholar
• 83 Alexander JH, Lopes RD, James S , et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365 (8) 699-708
  CrossrefPubMedGoogle Scholar
• 84 Bauersachs R, Berkowitz SD, Brenner B , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
  CrossrefPubMedGoogle Scholar
• 85 Schulman S, Kearon C, Kakkar AK , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
  CrossrefPubMedGoogle Scholar